PolyPid to Participate in Three Upcoming Fall Investor Conferences
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in three upcoming investor conferences:
- H.C. Wainwright 26th Annual Global Investment Conference: On-demand presentation available from September 9, 2024, at 7:00 AM ET.
- Lytham Partners Fall 2024 Investor Conference: On-demand fireside chat available from October 1, 2024, for 90 days.
- Sidoti & Company Micro-Cap Virtual Conference: Scheduled for November 13-14, 2024.
The PolyPid management team will be available for one-on-one investor meetings during these events. Interested investors should contact the respective conference organizers directly to arrange meetings.
PolyPid (Nasdaq: PYPD), un'azienda biofarmaceutica in fase avanzata focalizzata sul miglioramento dei risultati chirurgici, ha annunciato la sua partecipazione a tre prossime conferenze per investitori:
- 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright: Presentazione on-demand disponibile dal 9 settembre 2024, alle 7:00 ET.
- Conferenza per Investitori Lytham Partners Autunno 2024: Chiacchierata informale on-demand disponibile dal 1 ottobre 2024, per 90 giorni.
- Conferenza Virtuale Micro-Cap di Sidoti & Company: In programma per il 13 e 14 novembre 2024.
Il team di gestione di PolyPid sarà disponibile per incontri individuali con gli investitori durante questi eventi. Gli investitori interessati devono contattare direttamente gli organizzatori delle rispettive conferenze per fissare appuntamenti.
PolyPid (Nasdaq: PYPD), una empresa biofarmacéutica en etapa avanzada enfocada en mejorar los resultados quirúrgicos, ha anunciado su participación en tres próximas conferencias para inversores:
- 26ª Conferencia Anual Global de Inversiones H.C. Wainwright: Presentación bajo demanda disponible a partir del 9 de septiembre de 2024, a las 7:00 AM ET.
- Conferencia de Inversores Otoño 2024 de Lytham Partners: Charla informal bajo demanda disponible desde el 1 de octubre de 2024, durante 90 días.
- Conferencia Virtual Micro-Cap de Sidoti & Company: Programada para el 13 y 14 de noviembre de 2024.
El equipo de gestión de PolyPid estará disponible para reuniones individuales con inversores durante estos eventos. Los inversores interesados deben contactar directamente a los organizadores de las respectivas conferencias para organizar reuniones.
PolyPid (Nasdaq: PYPD), 외과 수술 결과 개선에 중점을 둔 후기 단계의 바이오 제약 회사가 세 가지 예정된 투자자 회의에 참여한다고 발표했습니다:
- H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스: 2024년 9월 9일 오전 7시 ET부터 온디맨드 프레젠테이션 제공.
- Lytham Partners 2024년 가을 투자자 회의: 2024년 10월 1일부터 90일 동안 온디맨드 파이어사이드 채팅 제공.
- Sidoti & Company 마이크로캡 가상 회의: 2024년 11월 13-14일 예정.
PolyPid 경영진은 이러한 행사 동안 투자자와의 일대일 미팅이 가능합니다. 관심 있는 투자자는 각각의 회의 주최자에게 직접 연락하여 미팅을 조율해야 합니다.
PolyPid (Nasdaq: PYPD), une entreprise biopharmaceutique en phase avancée axée sur l'amélioration des résultats chirurgicaux, a annoncé sa participation à trois conférences pour investisseurs à venir :
- 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright : Présentation à la demande disponible à partir du 9 septembre 2024, à 7h00 ET.
- Conférence Investisseurs Automne 2024 de Lytham Partners : Discussion informelle à la demande disponible à partir du 1er octobre 2024, pendant 90 jours.
- Conférence Virtuelle Micro-Cap de Sidoti & Company : Prévue pour le 13 et 14 novembre 2024.
Le comité de direction de PolyPid sera disponible pour des réunions individuelles avec les investisseurs lors de ces événements. Les investisseurs intéressés doivent contacter directement les organisateurs des conférences respectives pour organiser des réunions.
PolyPid (Nasdaq: PYPD), ein Biopharma-Unternehmen in der späten Phase, das sich auf die Verbesserung chirurgischer Ergebnisse konzentriert, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen bekanntgegeben:
- 26. Jährliche Globale Investorenkonferenz von H.C. Wainwright: On-Demand-Präsentation ab dem 9. September 2024, um 7:00 Uhr ET verfügbar.
- Lytham Partners Herbst 2024 Investorenkonferenz: On-Demand-Gespräch ab dem 1. Oktober 2024 für 90 Tage verfügbar.
- Sidoti & Company Mikro-Cap Virtuelle Konferenz: Geplant für den 13. und 14. November 2024.
Das Management-Team von PolyPid wird während dieser Veranstaltungen für persönliche Treffen mit Investoren zur Verfügung stehen. Interessierte Investoren sollten direkt die jeweiligen Konferenzveranstalter kontaktieren, um Meetings zu vereinbaren.
- None.
- None.
PETACH TIKVA, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in the following three investor conferences:
H.C. Wainwright 26th Annual Global Investment Conference
PolyPid’s presentation will be available on-demand beginning on Monday, September 9, 2024, at 7:00 AM ET and throughout the conference, via the conference platform.
Lytham Partners Fall 2024 Investor Conference
PolyPid’s fireside chat will be available on-demand beginning on Tuesday, October 1, 2024, via the conference platform and for 90 days thereafter on the Lytham investor portal.
Sidoti & Company Micro-Cap Virtual Conference
Conference Date: November 13-14, 2024
The PolyPid management team will participate in one-on-one investor meetings during these events. Investors interested in meeting with PolyPid at the conferences should contact the appropriate conference directly.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com
FAQ
What investor conferences will PolyPid (PYPD) attend in Fall 2024?
When is PolyPid's (PYPD) presentation at the H.C. Wainwright conference available?
How long will PolyPid's (PYPD) fireside chat be accessible for the Lytham Partners conference?
What are the dates for the Sidoti & Company Micro-Cap Virtual Conference that PolyPid (PYPD) is attending?
Can investors meet with PolyPid's (PYPD) management team during these conferences?
